MEETING - Symposium entitled "Progress in Clinical Pacing" (Italy) December 2000:
This article was originally published in Clinica
Executive Summary
Rome's international conference support service, AISC, will hold its 9th international symposium entitled "Progress in Clinical Pacing" at the Cavalieri Hilton Hotel, in Rome, Italy on December 5-8. Topics for discussion include: atrial fibrillation: clinical aspects; atrial electrical and mechanical remodelling; the atrial cardioverter-defibrillator; surgery for atrial fibrillation; new indications for cardiac pacing; bioventricular pacing to treat heart failure; lead delivery and extraction systems; implantable devices for diagnostic purposes; new ablation catheters; built-in holter monitoring; heart-brain interactions; and surgical treatment of cardiac arrhythmias. For more information contact the conference secretariat. Tel: +39 06 809 681. Fax: +39 06 808 8491. Email: [email protected] www.aisc.it
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.